Xoma Kills Gevokizumab, Reveals Another 44 Job Cuts

Xoma Inc. finally stopped all development for gevokizumab, shifting its entire focus to endocrine diseases and cutting even more jobs, but the company somehow expects to sell the asset to another party after racking up another Phase III clinical trial failure.